SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Democratic midterm gains, with traders expecting Democrats to control Congress, have focused attention on DJT as a political setback for Trump and a potential headwind for the company. The conversation is overwhelmingly bearish, with some traders expecting more political and policy pressure, while others argue Trumps veto power could limit the impact.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democrats midterm gains and control of Congress are driving a volatile SPY conversation, with traders focused on an overnight drop followed by a sharp rebound. Views diverge on whether gridlock and reduced uncertainty support stocks or whether potential scrutiny of AI and data-center spending poses a broader-market risk.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs earnings beat and upbeat outlook, driven by strong AI and data-center demand, sparked bullish discussion about its growth prospects. Traders also questioned whether the rally can hold, citing valuation, cash-flow and PC-market concerns, as well as speculation that election results could bring tighter data-center restrictions.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in the midterms triggered a sharp QQQ selloff followed by a strong rebound, as traders debated whether reduced election uncertainty and divided government would support stocks or whether potential limits on AI and data-center expansion could weigh on tech shares. The community remains split between calling the recovery a relief rally and viewing it as a temporary bounce amid policy concerns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

A strong quarterly report and raised full-year outlook, fueled by AI-server demand, are driving attention; bullish traders see growth and a potential rebound, while skeptics question thin margins, cash conversion and the companys credibility. Election-related concerns about AI and data-center regulation have added volatility to the post-earnings reaction.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisks Q3 results and raised outlook, with strong demand for the oral Wegovy launch, are driving attention. Traders are weighing that growth against weaker diabetes sales, U.S. pricing pressure and Lillys competitive gains, with some questioning whether the upbeat results can sustain a stock recovery.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Concerns about purported free, AI-built open-source alternatives to Adobes creative softwareand a Wells Fargo downgrade citing competition and growth risksare weighing on sentiment. Traders disagree over whether the clones threaten paid subscriptions and Adobes moat or are too immature to replace its professional and enterprise workflows; bulls also point to recurring revenue and cash flow.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos Q3 results are driving attention: faster daily-user growth, revenue and bookings above expectations, and a raised outlook are set against an EPS miss. Traders are split between welcoming the growth and guidance and questioning valuation, profitability, and AI-related risks, with shares pulling back after an initial post-earnings pop.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,984.36452344 USD and is up -0.00 over the last 24 hours. It is currently trading on 12773 active market(s) with $23,094,171,945.49 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention around the U.S. midterm results and anticipated Democratic gains in Congress, with traders debating whether policy and regulatory concerns are weighing on crypto or whether political gridlock and reduced uncertainty could help. Bearish posts point to market weakness and a potentially tougher regulatory climate, while bulls call the move a buying opportunity and argue Bitcoin is largely independent of U.S. politics.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs strong quarterly results and raised outlook, supported by demand for AI data-center connectivity and the Scorpio product ramp, are the main focus. Traders are split over the stocks weak, volatile reaction despite the report, weighing growth prospects against rich valuation and sell-the-news pressure.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Equity

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.


Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of +70.59% and +33.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates

BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -4.00% and +23.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera (BFRI) Q1 2026 Earnings Transcript

Transcript: Biofrontera Q1 2026 Earnings Conference Call

Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Biofrontera Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Bristol Myers Squibb faces an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy.</li><li>Scholar Rock’s Isembyld and Biofrontera's (BFRI) Ameluz received FDA clearance ahead of their scheduled late-September PDUFA dates.</li><li>Mirum Pharmaceuticals’ Atebrioz got FDA approval on Friday for patients aged 12-18 with an ultra-rare genetic disease.</li></ul>Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-September decisions have already received regulatory clearance.Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) awaits an FDA decision on expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle blocks blood flow. Stockholm-listed Egetis Therapeutics also faces a decision on Emcitate for MCT8 deficiency, a rare genetic disorder that affects how thyroid hormones reach the brain and other tissues.Meanwhile, Biofrontera (BFRI) and Scholar Rock (SRRK) entered the week with decisions originally scheduled for this period, while Mirum Pharmaceuticals (MIRM) and Incyte (INCY) received FDA approval for Atebrioz late last week.A PDUFA date is the target deadline by which the FDA aims to complete its review of a drug application.<img src="https://news.stocktwits-cdn.com/4_Hpst_fda_decisions_this_week_1_7833148823.png" alt="4Hpst-fda-decisions-this-week- (1).png"><h2 class="st-heading-2">Bristol Myers Awaits Camzyos Label Expansion</h2>The FDA is scheduled to make a decision on Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) on September 30. The regulatory body will decide whether to expand the use of Camzyos (Mavacamten) to adolescents ages 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Obstructive HCM is a condition in which the heart muscle becomes abnormally thick, potentially blocking blood flow out of the heart. Patients can experience shortness of breath, fatigue and chest pain.Camzyos is already FDA-approved for certain adults with symptomatic oHCM. Bristol Myers said the safety profile among adolescents was similar to that previously observed in adults.If cleared, Camzyos would become the first cardiac myosin inhibitor approved in the U.S. for adolescents with oHCM, according to the company.<h2 class="st-heading-2">Egetis Awaits FDA Decision On Rare Genetic Disorder Drug</h2>Egetis Therapeutics faces a September 28 decision on Emcitate for MCT8 deficiency.If approved, Emcitate would become the first FDA-approved treatment for MCT8 deficiency in the U.S. The drug is already approved in the European Union, and the FDA has already granted the application Priority Review. Emcitate has also received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations from the FDA.<h2 class="st-heading-2">FDA Already Acted On Several Late-September Decisions</h2>Several other drugs that had been heading toward FDA decisions around this week have already received regulatory clearance.Scholar Rock’s (SRRK) Isembyld was scheduled for a September 30 PDUFA date, but the FDA approved the treatment on Sept. 11 for adults and children aged two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.Spinal muscular atrophy is a rare genetic disease that causes progressive muscle weakness and loss of motor function. Scholar Rock said Isembyld is the first and only muscle-targeted treatment approved for SMA. However, SRRK shares are down more than 12% since the approval.Biofrontera’s (BFRI) Ameluz also received an FDA decision ahead of its September 28 PDUFA date. The label expansion covers Ameluz photodynamic therapy for superficial basal cell carcinoma, a common form of skin cancer. BFRI shares have seen an even sharper decline, down 23% since the FDA decision on September 14.<h2 class="st-heading-2">Mirum Gets FOP Drug Approval</h2>On Friday, the FDA approved Mirum Pharmaceuticals’ (MIRM) Atebrioz for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disease that causes bone to form in muscles and other soft tissues, gradually restricting movement.Mirum expects Atebrioz to become available in the U.S. in October.The biotech firm acquired worldwide rights to Atebrioz from Incyte (INCY) earlier this year. Incyte remains eligible for milestone payments and royalties from the drug.MIRM shares closed Friday’s session 0.4% higher and are currently trading up 3% in pre-market.<h2 class="st-heading-2">How Have BFRI, <a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>, SRRK, MIRM And INCY Performed YTD?</h2><img src="https://news.stocktwits-cdn.com/Biotech_63ba5c5882.png" alt="Biotech.png">Among these stocks, Biofrontera (BFRI) has gained the most this year, rising nearly 63%, followed by Incyte (INCY) at more than 22% and Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) at about 18%. Scholar Rock (SRRK) and Mirum Pharmaceuticals (MIRM) have each gained roughly 13%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/critical-minerals-wrap-crml-grml-surge-on-greenland-deal-us-stockpile-push-accelerates-as-trump-xi-talks-put-rare-earths-in-spotlight/cZMg2lHRBOY">Critical Minerals Wrap: CRML, GRML Surge On Greenland Deal, US Stockpile Push Accelerates As Trump-Xi Talks Put Rare Earths In Spotlight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-S

Current Price	$0.8899
Prev Close	$0.8701
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$1.13
Beta	0.84
Avg. Volume	240,994.73
PE Ratio	-1.52

52-Week High	$1.66
52-Week Low	$0.5547
Market Capitalization	$12.92M
EPS (Annual)	-$1.04
Price to Book	2.12
Revenue Per Employee	$453,315.22

Feed

News

Sentiment

Earnings

Fundamentals

Info

BFRI Fundamentals